Cannot let pharma industry ‘run amok’ in name of free market: SC

The Supreme Court criticized medicine MRPs that were exponentially higher than the prices at which companies sold the medicines to retailers. The bench said the pharmaceutical industry could not be allowed to “run amok” in the name of a free market. It was especially concerned about the burden on ordinary patients.

The court repeatedly asked the Centre to explain why such a large difference existed and who ultimately benefited. It said it was “pained by the loot” and questioned whether commerce should take precedence over citizens’ lives. The concern was not simply that prices were high, but that the pricing system appeared difficult to justify.

The court reserved its order on bringing all non-patented medicines and medical consumables under price control. The Centre argued that competition keeps Indian medicine prices among the world’s lowest. The judges remained unconvinced because the government could not explain the extreme price differences.

A medicine’s maximum retail price, or MRP, is the highest price printed or declared for its sale to a consumer. It functions as a ceiling for the retail transaction. It is different from the price charged by a manufacturer or supplier when selling the product to a retailer.

For example, if a company sells a medicine to a retailer for Rs 100 but sets its MRP at Rs 1,100, the retailer-facing price and consumer-facing ceiling are very different. The gap can provide room for discounts, distribution margins, or other commercial margins. The article focuses on cases where the gap becomes exceptionally large.

The Supreme Court asked the Centre to justify these differences and identify who benefits from them. The government defended competition and said Indian medicine prices are among the lowest globally. The judges wanted a clearer explanation of how that claim protects patients facing high final prices.

The article says that in some cases, a medicine’s MRP was over 1,000% of the price at which it was sold to retailers. Read literally, that means the MRP exceeded ten times the retailer-facing price. The scale is striking because the gap appears before the medicine reaches the patient.

Suppose a retailer bought a medicine for Rs 100. An MRP above 1,000% of that amount would be above Rs 1,000. If someone instead uses “a 1,000% markup” to mean a 1,000% increase, the final price would be above Rs 1,100. The article uses the first comparison: MRP as a percentage of retailer price.

The Supreme Court treated the gap as evidence requiring justification, not as an ordinary commercial difference. It asked the Centre why such pricing was permitted and who benefited. The court’s concern was that patients, rather than companies or other participants, ultimately carried the cost.

A very high MRP can create greater room between a medicine’s supply price and its possible retail price. The article does not identify a specific beneficiary in each case. However, the Supreme Court repeatedly asked who ultimately benefits and said the policy appeared to benefit corporate interests rather than poor patients.

The court challenged the Centre because it could not explain why medicines were sold to retailers at prices dramatically below their MRPs. The judges asked whether the pharmaceutical industry should be allowed to “run amok” and why the entire system seemed to work for “few people.” These questions focused on the distribution of financial gains.

The government argued that free-market competition keeps medicine prices among the lowest in the world. The court did not accept that answer as sufficient. Its reserved order on wider price controls could affect how non-patented medicines and medical consumables are priced, depending on the eventual decision and government response.

When essential medicines cost far more than their production or wholesale price, patients must spend more to obtain treatment. Families may have less money for other needs, and poor patients face the greatest pressure. The article describes this as suffering borne by the common man.

The mechanism is the gap between the price paid by retailers and the high MRP charged at the final sale. For instance, when a medicine reaches retailers at a price far below its stated MRP, the patient may still face the higher amount. The Supreme Court called this situation “loot” and demanded an explanation.

The Centre said India’s medicine prices are among the lowest worldwide because of free-market competition. The court remained concerned that this broad claim did not answer the problem of extreme gaps. It reserved its order on extending price controls, leaving the possible effect on patients and families unresolved.

The Drugs (Prices Control) Order, or DPCO, is the government’s framework for controlling prices of medicines placed within its regulated schedule. Price control limits how much certain medicines may be sold for. The article contrasts these scheduled drugs with products outside that mechanism.

The Supreme Court was considering a plea to bring all non-patented medicines and medical consumables under price control, similar to scheduled drugs. The article does not provide the complete criteria for deciding which products enter the schedule. It does show that the current system does not automatically regulate every medicine or supply.

The Centre said the government had already acted by deciding to cap prices of anti-cancer drugs. The court said the government had “woken up” only after judicial intervention, while the government replied that deliberations were already underway. The order was reserved, so the article gives no final decision on wider coverage.

Medicine prices are shaped by several forces. Competition can pressure companies to lower prices. A patent can give its holder temporary exclusive rights, reducing direct competition for that medicine. Generic medicines usually increase competition by offering equivalent treatment options after relevant exclusivity ends. Governments can add price controls when affordability or access becomes a concern.

The balance is practical, not automatic. More competing suppliers may reduce prices, while limited competition can leave companies with greater pricing power. A government price ceiling can restrict that power, but it must decide which medicines and products to regulate. The article identifies scheduled drugs as covered by the existing mechanism and asks whether coverage should expand.

In this case, the Centre argued that free-market competition keeps Indian prices among the lowest worldwide. The Supreme Court questioned whether competition alone explains MRPs exceeding retailer prices by over 1,000%. It reserved its order on wider controls, so the article leaves the next policy direction open.